1
|
Yi G, Li H, Li Y, Zhao F, Ying Z, Liu M, Zhang J, Liu X. The protective effect of soybean protein-derived peptides on apoptosis via the activation of PI3K-AKT and inhibition on apoptosis pathway. Food Sci Nutr 2020; 8:4591-4600. [PMID: 32884739 PMCID: PMC7455986 DOI: 10.1002/fsn3.1776] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 06/10/2020] [Accepted: 06/11/2020] [Indexed: 12/11/2022] Open
Abstract
Soybean protein-derived peptides (SBP) are a rich source of various bioactive peptides with multiple health benefits. However, the prospective effects of SBP on human cells are still unclear. Therefore, this article investigated the effects of small molecular weight SBP on MG132-induced apoptosis in RAW264.7 cells. SBP inhibited MG132-induced apoptosis of RAW264.7 cells in a dose-dependent manner by flow cytometry. To further study its molecular mechanisms, Western blot analysis demonstrated that SBP could activate the PI3K-AKT pathway by increasing the phosphorylation of PI3K and AKT and inhibiting apoptosis pathway by downregulating the expressions of pro-apoptotic proteins of Bim, Bax, Fas, and Fasl and promoting the expressions of anti-apoptotic proteins of Bcl-xL and Bcl-2. These results indicated the protective effect of SBP on MG132-induced apoptosis in RAW264.7 cells.
Collapse
Affiliation(s)
- Guofu Yi
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - He Li
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - You Li
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - Fen Zhao
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - Zhiwei Ying
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - Menglan Liu
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - Jian Zhang
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| | - Xinqi Liu
- Beijing Advanced Innovation Center for Food Nutrition and Human HealthBeijing Engineering and Technology Research Center of Food AdditivesBeijing Technology and Business University (BTBU)BeijingChina
| |
Collapse
|
2
|
Gu L, Ye P, Li H, Wang Y, Xu Y, Tian Q, Lei G, Zhao C, Gao Z, Zhao W, Tan S. Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE -/- mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway. FASEB J 2019; 33:4836-4850. [PMID: 30601695 DOI: 10.1096/fj.201802251r] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2024]
Abstract
Oxidative stress-induced vascular endothelial cell (VEC) injury is a major mechanism in the initiation and development of atherosclerosis. Lunasin, a soybean-derived 43-aa peptide, has been previously shown to possess potent antioxidant and anti-inflammatory activities other than its established anticancer activities. This study investigated the effects of lunasin on protecting VECs from oxidative damage and inhibiting atherosclerotic plaque progression in apolipoprotein E-deficient (ApoE-/-) mice and explored its underlying mechanism. Biochemical and histologic analyses were performed by using EA.hy926 human VECs and a high-fat diet (HFD) ApoE-/- mouse atherosclerosis model. Our data indicated that lunasin attenuated H2O2-induced, mitochondria-dependent endothelial apoptosis via down-regulating Bax and up-regulating Bcl-2, inhibiting the mitochondrial depolarization, and reducing the release of cytochrome c, as well as decreasing the activation of caspase-9 and caspase-3 in vitro and in vivo. Mechanic studies showed that lunasin significantly up-regulated heme oxygenase-1 via the PI3K/Akt/nuclear factor erythroid 2-related factor 2/antioxidant response element pathway, and reduced H2O2-induced ROS production in VECs, thereby attenuating oxidant-induced endothelial injury and inhibiting atherosclerotic plaque progression in ApoE-/- mice. In conclusion, our in vitro and in vivo data suggest that lunasin protects VECs from oxidative damage by enhancing heme oxygenase-1 expression via activation of the PI3K/Akt/nuclear factor erythroid 2-related factor 2/antioxidant response element pathway and inhibiting mitochondria-dependent apoptosis, thereby effectively attenuating atherosclerosis in HFD-fed ApoE-/- mice. Lunasin may act as a potential therapeutic agent for the prevention and treatment of atherosclerosis.-Gu, L., Ye, P., Li, H., Wang, Y., Xu, Y., Tian, Q., Lei, G., Zhao, C., Gao, Z., Zhao, W., Tan, S. Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE-/- mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway.
Collapse
Affiliation(s)
- Lili Gu
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Pei Ye
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Hengli Li
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Yue Wang
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Yaqiong Xu
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Qinghua Tian
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Gaoxin Lei
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Cheng Zhao
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Zhan Gao
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Wenfeng Zhao
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| | - Shuhua Tan
- State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China
| |
Collapse
|
4
|
Devapatla B, Shidal C, Yaddanapudi K, Davis KR. Validation of syngeneic mouse models of melanoma and non-small cell lung cancer for investigating the anticancer effects of the soy-derived peptide Lunasin. F1000Res 2016; 5:2432. [PMID: 28299174 DOI: 10.12688/f1000research.9661.1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/28/2016] [Indexed: 11/20/2022] Open
Abstract
Background : Lunasin is a naturally occurring peptide present in soybean that has both chemopreventive and therapeutic activities that can prevent cellular transformation and inhibit the growth of several human cancer types. Recent studies indicate that Lunasin has several distinct potential modes of action including suppressing integrin signaling and epigenetic effects driven by modulation of histone acetylation. In addition to direct effects on cancer cells, Lunasin also has effects on innate immunity that may contribute to its ability to inhibit tumor growth in vivo. Methods: Standard assays for cell proliferation and colony formation were used to assess Lunasin's in vitro activity against murine Lewis lung carcinoma (LLC) and B16-F0 melanoma cells. Lunasin's in vivo activity was assessed by comparing the growth of tumors initiated by subcutaneous implantation of LLC or B16-F0 cells in Lunasin-treated and untreated C57BL/6 mice. Results: Lunasin was found to inhibit growth of murine LLC cells and murine B16-F0 melanoma cells in vitro and in wild-type C57BL/6 mice. The effects of Lunasin in these two mouse models were very similar to those previously observed in studies of human non-small cell lung cancer and melanoma cell lines. Conclusions: We have now validated two established syngeneic mouse models as being responsive to Lunasin treatment. The validation of these two in vivo syngeneic models will allow detailed studies on the combined therapeutic and immune effects of Lunasin in a fully immunocompetent mouse model.
Collapse
Affiliation(s)
- Bharat Devapatla
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, , Louisville, KY, 40402, USA
| | - Chris Shidal
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, , Louisville, KY, 40402, USA; Department of Biology and Biotechnology Program, Indiana University, Bloomington, IN, 47405, USA
| | - Kavitha Yaddanapudi
- Department of Medicine and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, 40402, USA
| | - Keith R Davis
- Department of Biology and Biotechnology Program, Indiana University, Bloomington, IN, 47405, USA
| |
Collapse
|
5
|
Devapatla B, Shidal C, Yaddanapudi K, Davis KR. Validation of syngeneic mouse models of melanoma and non-small cell lung cancer for investigating the anticancer effects of the soy-derived peptide Lunasin. F1000Res 2016; 5:2432. [PMID: 28299174 PMCID: PMC5325107 DOI: 10.12688/f1000research.9661.2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/16/2017] [Indexed: 01/24/2023] Open
Abstract
Background: Lunasin is a naturally occurring peptide present in soybean that has both chemopreventive and therapeutic activities that can prevent cellular transformation and inhibit the growth of several human cancer types. Recent studies indicate that Lunasin has several distinct potential modes of action including suppressing integrin signaling and epigenetic effects driven by modulation of histone acetylation. In addition to direct effects on cancer cells, Lunasin also has effects on innate immunity that may contribute to its ability to inhibit tumor growth
in vivo. Methods: Standard assays for cell proliferation and colony formation were used to assess Lunasin’s
in vitro activity against murine Lewis lung carcinoma (LLC) and B16-F0 melanoma cells. Lunasin’s
in vivo activity was assessed by comparing the growth of tumors initiated by subcutaneous implantation of LLC or B16-F0 cells in Lunasin-treated and untreated C57BL/6 mice. Results: Lunasin was found to inhibit growth of murine LLC cells and murine B16-F0 melanoma cells
in vitro and in wild-type C57BL/6 mice. The effects of Lunasin in these two mouse models were very similar to those previously observed in studies of human non-small cell lung cancer and melanoma cell lines. Conclusions: We have now validated two established syngeneic mouse models as being responsive to Lunasin treatment. The validation of these two
in vivo syngeneic models will allow detailed studies on the combined therapeutic and immune effects of Lunasin in a fully immunocompetent mouse model.
Collapse
Affiliation(s)
- Bharat Devapatla
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, , Louisville, KY, 40402, USA
| | - Chris Shidal
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, , Louisville, KY, 40402, USA; Department of Biology and Biotechnology Program, Indiana University, Bloomington, IN, 47405, USA
| | - Kavitha Yaddanapudi
- Department of Medicine and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, 40402, USA
| | - Keith R Davis
- Department of Biology and Biotechnology Program, Indiana University, Bloomington, IN, 47405, USA
| |
Collapse
|